One-year outcomes of Aflibercept for refractory diabetic macular edema in Bevacizumab nonresponders

Abstract

Our data from a real-world clinical setting highlight the efficacy of Aflibercept as an alternative therapeutic option for DME recalcitrant to Bevacizumab, with potential additional benefit to those with worse vision, greater CST, and better glycemic control at baseline.